JP2017537082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537082A5 JP2017537082A5 JP2017525343A JP2017525343A JP2017537082A5 JP 2017537082 A5 JP2017537082 A5 JP 2017537082A5 JP 2017525343 A JP2017525343 A JP 2017525343A JP 2017525343 A JP2017525343 A JP 2017525343A JP 2017537082 A5 JP2017537082 A5 JP 2017537082A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- antibody
- item
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 9
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 230000022534 cell killing Effects 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 18
- 239000012634 fragment Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078849P | 2014-11-12 | 2014-11-12 | |
| US62/078,849 | 2014-11-12 | ||
| PCT/US2015/060465 WO2016077638A1 (en) | 2014-11-12 | 2015-11-12 | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537082A JP2017537082A (ja) | 2017-12-14 |
| JP2017537082A5 true JP2017537082A5 (OSRAM) | 2018-12-20 |
| JP6779873B2 JP6779873B2 (ja) | 2020-11-04 |
Family
ID=55955081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525343A Expired - Fee Related JP6779873B2 (ja) | 2014-11-12 | 2015-11-12 | 抗コンドロイチン硫酸プロテオグリカン４抗体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11091547B2 (OSRAM) |
| EP (1) | EP3218413A4 (OSRAM) |
| JP (1) | JP6779873B2 (OSRAM) |
| AU (1) | AU2015346205B2 (OSRAM) |
| CA (1) | CA2967350C (OSRAM) |
| WO (1) | WO2016077638A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| AU2019287676A1 (en) * | 2018-06-13 | 2021-01-07 | The General Hospital Corporation | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| IL297495A (en) | 2020-04-22 | 2022-12-01 | Dragonfly Therapeutics Inc | Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins |
| CN111575241B (zh) * | 2020-05-29 | 2022-09-13 | 复旦大学附属眼耳鼻喉科医院 | 一种嵌合硫酸软骨素蛋白多糖4受体的t淋巴细胞及其制备方法和用途 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3184394A1 (en) * | 2020-06-29 | 2022-01-06 | Gianpietro Dotti | Methods and compositions for the reduction of chimeric antigen receptor tonic signaling |
| CN114249832B (zh) * | 2020-09-24 | 2023-11-10 | 博源润生医药（杭州）有限公司 | 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4347654A1 (en) * | 2021-06-04 | 2024-04-10 | Amgen Research (Munich) GmbH | T cell engager molecules and uses thereof |
| US20250313648A1 (en) * | 2021-12-07 | 2025-10-09 | Regents Of The University Of Minnesota | Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| CA2682382A1 (en) * | 2007-03-28 | 2008-10-09 | Biogen Idec Inc. | Non-fucosylated antibodies |
| JP2012503203A (ja) * | 2008-09-19 | 2012-02-02 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体 |
| CA2737597C (en) * | 2008-10-16 | 2017-03-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| WO2011009090A1 (en) * | 2009-07-16 | 2011-01-20 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
| KR101508043B1 (ko) | 2009-09-29 | 2015-04-06 | 로슈 글리카트 아게 | 이중특이적 사멸 수용체 아고니스트성 항체 |
| AU2011268110B2 (en) * | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| EP2646054A4 (en) * | 2010-12-02 | 2015-03-04 | Univ Pittsburgh | METHOD FOR THE TREATMENT OF A TUMOR WITH THE HELP OF AN ANTIBODY FOR SPECIFIC BINDING TO GRP94 |
| DK2794658T3 (en) * | 2011-12-19 | 2017-06-19 | Synimmune Gmbh | BISPECIFIC ANTIBODY MOLECULE |
| CA2862448A1 (en) * | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| EP4053162A1 (en) | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| EA201891502A1 (ru) * | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| JP6420776B2 (ja) * | 2013-03-05 | 2018-11-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫療法のためのエンゲージャー細胞 |
| US10220091B2 (en) * | 2013-04-04 | 2019-03-05 | The General Hospital Corporation | Combination treatments with sonic hedgehog inhibitors |
-
2015
- 2015-11-12 JP JP2017525343A patent/JP6779873B2/ja not_active Expired - Fee Related
- 2015-11-12 EP EP15858791.5A patent/EP3218413A4/en not_active Withdrawn
- 2015-11-12 AU AU2015346205A patent/AU2015346205B2/en not_active Ceased
- 2015-11-12 US US15/526,309 patent/US11091547B2/en active Active
- 2015-11-12 WO PCT/US2015/060465 patent/WO2016077638A1/en not_active Ceased
- 2015-11-12 CA CA2967350A patent/CA2967350C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537082A5 (OSRAM) | ||
| US11319372B2 (en) | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) | |
| AU2016233495B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| US11384139B2 (en) | Antibody targeting cell surface deposited complement protein C3d and use thereof | |
| JP2025069305A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP2013532968A5 (OSRAM) | ||
| CA2939293A1 (en) | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies | |
| JP2012526558A5 (OSRAM) | ||
| JP2018520667A5 (OSRAM) | ||
| JP2018510617A5 (OSRAM) | ||
| US11242398B2 (en) | Anti-OX40 antibodies and methods of activating OX40 | |
| RU2768404C2 (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| JP2024513921A (ja) | 抗ｃｄ１２２抗体及びその使用 | |
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| JP2021512159A5 (OSRAM) | ||
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JP2016529213A5 (OSRAM) | ||
| WO2022095934A1 (zh) | 抗Siglec-15抗体及其在制备药物中的应用 | |
| US20250051440A1 (en) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling | |
| EP4620973A1 (en) | Antibodies targeting cell surface deposited complement protein c3d and use thereof | |
| WO2025128264A1 (en) | Anti-pd-1 monoclonal antibody and methods of use thereof | |
| JP2025541365A (ja) | 多価造血細胞係合因子または活性化因子 | |
| CA3210910A1 (en) | Anti-pd-l1 antibody and use thereof |